Comparing two treatments for advanced stomach cancer after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with adenocarcinoma (a common type of cancer) in the stomach or where the stomach meets the food pipe.
- Your cancer has spread or cannot be removed with surgery, and it got worse within 6 months of your last treatment.
- You have had at least one prior chemotherapy that included drugs like fluorouracil or capecitabine and either cisplatin or oxaliplatin. If your cancer is HER2-positive, you also need to have had trastuzumab.
- You are able to take pills by mouth and your daily activity is not too limited (you can do light work or are fully active).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
This study tests whether a combination of ramucirumab, nal-IRI (irinotecan liposome), and trifluridine/tipiracil can work better as a second treatment for metastatic stomach cancer. It may help people whose cancer has returned or progressed after only one prior treatment plan.
This trial tests a combination of three drugs for advanced stomach or esophagus cancer that hasn't been treated much. The goal is to see if this combination helps shrink or control the cancer.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a new combination of medications (IBI363 plus bevacizumab, with or without nab-paclitaxel) for people with advanced stomach cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth better than existing options.
Hear when a new Clinical Stage III Gastric Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.